Breaking News
Get 50% Off 0
📈 Q2 Earnings Alert! Critical earnings dates you can't miss
See Calendar
Close

Nxera Pharma Co Ltd (4565)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
877.0 -4.0    -0.45%
25/07 - Closed. Currency in JPY
Type:  Equity
Market:  Japan
ISIN:  JP3431300007 
  • Volume: 580,200
  • Bid/Ask: 877.0 / 879.0
  • Day's Range: 873.0 - 893.0
Nxera Pharma 877.0 -4.0 -0.45%

Nxera Pharma Co Ltd Company Profile

 
Get an in-depth profile of Nxera Pharma Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

374

Equity Type

ORD

Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist in phase 2 trial for narcolepsy and preclinical trial for EDS in neurology. Its products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; PF-06954522, a GLP-1 agonist for metabolic diseases; and NBI-1117570, a dual muscarinic M1/M4 agonist, NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; NXE0048149, a GPR52 agonist for schizophrenia; and NXE0039732, an EP4 antagonist for immuno-oncology. The company’s products in preclinical trial comprise NBI-1117567, a muscarinic M1-preferring agonist for neurology; KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. It also develops other discovery-stage drugs. The company has strategic collaborations with Verily, PeptiDream, Tempero Bio, Pharmenable Therapeutics, Kallyope, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Boehringer Ingelheim, Lilly, AbbVie, Biohaven pharmaceuticals, Takeda, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and PrecisionLife. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato-ku, Japan.

Contact Information

Address Midtown East 9-7-2 Akasaka
Minato, 107-0052
Japan
Phone 81 3 5962 5718
Fax -

Top Executives

Name Age Since Title
Angela J. Russell - 2023 Member of Scientific Advisory Board
Noriaki Nagai 68 2019 External Independent Director
David Roblin 59 2018 Independent External Director
Peter R. Bernstein - - Member of Scientific Advisory Board
Richard Henderson - - Member of Scientific Advisory Board
Paul Leeson - - Member of Scientific Advisory Board
Miwa Seki 60 2022 External Independent Director
Rolf Kristian Berndtson Soderstrom 60 2020 Independent External Director
Malcolm Weir 67 2020 Member of Scientific Advisory Board
Christopher Cargill 41 2017 Representative Executive Officer, President, CEO & Director
Chris Tate - - Member of Scientific Advisory Board
Sheena Radford - 2023 Member of Scientific Advisory Board
John Parkinson - 2022 Member of Scientific Advisory Board
Duncan Richards - 2023 Member of Scientific Advisory Board
Eiko Tomita 64 2023 Independent External Director
Yoshiyasu Ninomiya - 2025 Member of Scientific Advisory Board
Takeo Morooka - 2025 Member of Scientific Advisory Board
William A. M. Burns 78 2025 Member of Scientific Advisory Board
Nicola Rabson 51 2025 Outside Independent Director
Naoko Shimura 51 2025 Outside Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4565 Comments

Write your thoughts about Nxera Pharma Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email